System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish

PubMed: 39331092 DOI: 10.3233/CBM-240034

Blood endocan as a biomarker for breast cancer recurrence.

Cancer Biomark 41(2):145-154

Authors: Kentaro Daiki, Yoko Kanada, Aya Nagata, Kanae Taruno, Katsuhide Igarashi, Toshiko Yamochi, Hirotaka Ota, Fumiaki Sato, Seigo Nakamura, Yoshinori Kato

Affiliations

  • Laboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
  • Department of Breast Surgical Oncology, Tokyo Rosai Hospital, Tokyo, Japan.
  • Department of Breast Surgical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Institute for Clinical Genetics and Genomics, Showa University, Tokyo, Japan.
  • Laboratory of Biofunctional Science, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
  • Department of Pathology, Showa University School of Medicine, Tokyo, Japan.

Abstract

BACKGROUND

Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood.

OBJECTIVE

This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.

METHODS

Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3).

RESULTS

Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan.

CONCLUSIONS

Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.

MeSH

Blood, Breast Neoplasms, Neoplasms, Biomarkers, Breast